Welcome: Guest | Site Use Options | Register | Login |

Abcuro Inc

Profile last edited on: 1/31/2020
90 Bridge StreetSuite 100
Newton, MA 02458
  (617) 714-9759?
  corporate.contact@abcuro.com
  www.abcuro.com
Business Identifier: Next generation of T-Cell targeted bio-therapeutics
Public Profile:
A biopharmaceutical company, Acuro Inc.'s promising new target for cancer immunotherapy - KLRG1 - is part of the firm's effort to address developopment of a new generation of immunomodulatory therapeutics for treating both autoimmunity and cancer. The company uses proprietary analysis of transcriptome data from human disease to identify new approaches to target key compartments of the immune system. KLRG1 has recently emerged as an attractive target to restore anti-tumor immune function. An inhibitory receptor of T and NK cells, it functions to reduce the activity of highly differentiated immune cells by interacting with its ligands E/N cadherin. Abcuro has developed a blocking antibody directed toward KLRG1 that restores immune function.

 Synopsis: Awardee Business Condition
Year Founded First SBIR Year Date of Last Award
Employee Range VC funded? IP Holdings
Revenue Range Private/Public Exchange/Symbol :
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
Antibody Blockade of T Cell Activating Co-Inhibitory Receptor KLRG1 for Treatment of Melanoma

Unlock access

To unlock access to all SBIR-STTR company Profiles, a FREE site registration is required. Click here to register or login if you already have an account

Smart Office Options

SBIR firms in the news



Contact information

Innovation Development Institute, LLC

   45 Beach Bluff Avenue, Suite 300
     Swampscott,  MA 01907-1542

  Tel:  (781) 595-2920

  support@inknowvation.com